Sangamo Advances Fabry Gene Therapy Toward FDA Approval Amid Financial Strain
Event summary
- Sangamo initiated a rolling BLA submission for its Fabry disease gene therapy, ST-920, under the FDA's Accelerated Approval pathway.
- The company raised over $130 million in 2025 through non-dilutive license fees, milestone payments, and equity financing.
- Sangamo reported a net loss of $122.9 million for full-year 2025, with cash reserves dropping to $20.9 million by year-end.
- The company activated six clinical sites in its Phase 1/2 STAND study for chronic neuropathic pain and secured Fast Track Designation for ST-503.
The big picture
Sangamo Therapeutics is navigating a critical phase in its Fabry disease program, with the rolling BLA submission marking a potential inflection point. However, the company faces significant financial challenges, including declining cash reserves and increasing operating losses. Its strategic pivot toward neurology, bolstered by partnerships like Eli Lilly, could diversify its pipeline but requires sustained investment to realize long-term value.
What we're watching
- Regulatory Approval
- Whether the FDA will accept the rolling BLA submission for ST-920 and grant approval under the Accelerated Approval pathway.
- Financial Sustainability
- The pace at which Sangamo can secure additional funding to sustain operations beyond Q3 2026, given its current cash runway.
- Pipeline Progress
- How the advancement of neurology programs, particularly ST-503 for chronic neuropathic pain, will impact Sangamo's strategic shift toward neurology.
Our editorial coverage:
Related topics